Additionally, when grouping patients by subtype and using each gene list as a signature for KM analysis, NANOS1-, PUM2-, and CPSF4-responsive genes stratified DMFS for patients with the HER2-enriched subtype of breast cancer (Fig. S2a–c). This evidence concerns the gene ERBB2 and breast carcinoma.